In 2023, the sales of Musculo-Skeletal System medicines in Canada stood at an actual figure as of the beginning of the forecast period. From 2024 to 2028, forecasts indicate a steady increase in sales, growing from 969.9 million USD to 1030.0 million USD PPP by 2028. This marks a modest year-on-year growth, with the sales gradually increasing each year. Over the five-year forecast period from 2023 to 2028, the compound annual growth rate (CAGR) is projected to remain positive and stable.
Future trends to watch for include:
- Demographic shifts leading to higher demand for musculoskeletal treatments as the Canadian population ages.
- Technological advancements in musculoskeletal therapies driving innovation and potentially boosting market growth.
- Potential impact of healthcare policy changes on market dynamics and access to musculoskeletal treatments.
